FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
--------------

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BVF PARTNERS L P/IL  (Last) (First) (Middle)				DV	DYNAVAX TECHNOLOGIES CORP [DVAX ]  3. Date of Earliest Transaction (Month/Day/Year)							Relationship of Reporting Person(s) to Issuer (Check all applicable)      Director					
900 N. MICHIGAN AVE., SUITE 1100  (Street)				_	07/27/2009  4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
CHICAGO IL 60611  (City) (State) (Zip)			-	Form filed by One Reporting Person  X Form filed by More than One Reporting Person													
(City)	(5)		(Zip)	,ativ	Social	ritios A	cauir	od D	icnocod o	f or D	onofic	ially	Ownor	۸			
1. Title of Security (Instr. 3)			2. Transacti Date	2. Transaction		2A. Deemed Execution Date,	3. Transaction Code (Instr. 8)		A. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar		(A) or	5. Amount of Securities Beneficially Owned Foll		of G	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	irect Ir direct B	7. Nature of Indirect Beneficial Ownership
					(	,,	Code	v	Amount	(A) or (D)	Price	<b>─</b>   テ	Reported Fransactio Instr. 3 ar	on(s)	() (		nstr. 4)
Common	Stock		07/27/2	009			S		60,100(1)	D	\$1.99	919	6,253	,557	<b>D</b> <sup>(2</sup>	)	
Common	Stock		07/27/2	009			S		41,000(1)	D	\$1.99	919	6,212	,557	<b>D</b> (3	)	
Common	Stock		07/27/2	009			S		144,000(1)	D	\$1.99	919	6,068	,557	D <sup>(4</sup>	)	
Common	Stock		07/28/2	009			S		12,000(1)	D	\$1.85	503	6,056	,557	<b>D</b> <sup>(2</sup>	)	
Common	Stock		07/28/2	009			S		8,000(1)	D	\$1.85	503	6,048	,557	<b>D</b> (3	)	
Common	Stock		07/28/2	009			S		29,000(1)	D	\$1.85	503	6,019	,557	D <sup>(4</sup>	-)	
Common	Stock		07/29/2	009			S		27,500 <sup>(1)</sup>	D	\$1.85	533	5,992	,057	$\mathbf{D}^{(2)}$	)	
Common	Stock		07/29/2	009			S		19,000(1)	D	\$1.85	533	5,973	,057	<b>D</b> (3	9)	
Common	Stock		07/29/2	009			S		67,000(1)	D	\$1.85	533	5,906	,057	<b>D</b> <sup>(4</sup>	)	
Common	Stock												5,906,	,057	<b>I</b> (5)	p n e w	General artner and nanager of ntities with direct wnership.
Common	Stock												5,906	,057	I <sup>(6)</sup>	P e ii	General artner of ontity with ordirect wnership.
Common Stock													5,906,057		<b>I</b> <sup>(7)</sup>	si a d e ii	ole hareholder nd sole irector of ntity with ndirect wnership.
		Ta	able II - Derivat (e.g., p						posed of, convertib				wned				
Derivative   Conversion   Date   Execusive   Security   or Exercise   (Month/Day/Year)   if any		3A. Deemed Execution Date,	eemed 4. Ition Date, Trans Code		5. Number action of			rcisable and Date	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ov Fo Dii or (I)	vnership orm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A) (D)	Date Exer	cisable	Expiration Date	Title	Amount or Number of Shares						
1. Name ar	nd Address of	Reporting Person*															

BVF PARTNERS L P/IL								
(Last) 900 N. MICHIGAN	(First) AVE., SUITE 1100	(Middle)						
(Street) CHICAGO	IL	60611						
(City)	(State)	(Zip)						
1. Name and Address of BIOTECHNOLO	Reporting Person*  OGY VALUE FU	JND L P						
(Last) 900 N. MICHIGAN	(First) AVE., SUITE 1100	(Middle)						
(Street) CHICAGO	IL	60611						
(City)	(State)	(Zip)						
1. Name and Address of BIOTECHNOL	Reporting Person*	JND II LP						
(Last) 900 N. MICHIGAN	(First) AVE., SUITE 1100	(Middle)						
(Street) CHICAGO	IL	60611						
(City)	(State)	(Zip)						
1. Name and Address of Reporting Person*  BVF INVESTMENTS LLC								
(Last) 900 N. MICHIGAN	(First) AVE., SUITE 1100	(Middle)						
(Street) CHICAGO	IL	60611						
(City)	(State)	(Zip)						
1. Name and Address of LAMPERT MA								
(Last) 900 N. MICHIGAN	(First) AVE., SUITE 1100	(Middle)						
(Street) CHICAGO	IL	60611						
(City)	(State)	(Zip)						
1. Name and Address of BVF INC/IL	Reporting Person*							
(Last) 900 N. MICHIGAN	(First) AVE., SUITE 1100	(Middle)						
(Street) CHICAGO	IL	60611						
(City)  Explanation of Response	(State)	(Zip)						

## Explanation of Responses:

- 1. Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request.
- 2. Shares directly beneficially owned by Biotechnology Value Fund, L.P. ("BVF")  $\,$
- 3. Shares directly beneficially owned by Biotechnology Value Fund II, L.P. ("BVF II")
- 4. The shares of Common Stock are directly beneficially owned by BVF Investments, LLC ("BVFLLC"), a Delaware limited liability company. Pursuant to the operating agreement of BVFLLC, BVF Partners,

- L.P., a Delaware limited partnership ("Partners") is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVFLLC, in the shares of Common Stock and other securities and to vote, exercise or convert and dispose of such securities and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.
- 5. The shares of Common Stock are indirectly beneficially owned by Partners. Partners is the general partner of BVF and BVF II and is the manager of BVFLLC.
- 6. The shares of Common Stock are indirectly beneficially owned by BVF Inc., a Delaware corporation ("BVF Inc."). BVF Inc. is the general partner of Partners.
- 7. Mark N. Lampert is the sole shareholder, sole director, and an officer of BVF Inc.

## Remarks:

BVF Partners L.P., By: BVF 07/29/2009 Inc., its GP, By: /s/ Mark N. <u>Lampert</u> **BIOTECHNOLOGY VALUE** FUND, L.P. By: BVF Partners 07/29/2009 L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert **BIOTECHNOLOGY VALUE** FUND II, L.P., By: BVF 07/29/2009 Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert BVF INVESTMENTS, L.L.C., By: BVF Partners L.P., its 07/29/2009 Manager, By: BVF Inc., By: /s/ Mark N. Lampert BVF INC., By: /s/ Mark N. 07/29/2009 MARK N. LAMPERT By: /s/ 07/29/2009 Mark N. Lampert \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.